A blog exploring pharmaceutical relationship marketing, emarketing and innovation with a focus on rare disorders.
SirenWired
The convergence of rare disease, digital communications, and pharmaceutical marketing communications

#SocPharm Tweetchat Transcript 10/20/2010

Posted by | 9:31pm on Wednesday, October 20, 2010

:
First live #SocPharm Tweetchat. Held at #digpharm w/questions & responses coming from both the real-life audience & Twitter.

:
We’ll assume that all tweets within #socpharm are your own and not your employers (unless you specfically decalre them)

:
t1: What’s been the overall feedback/response to the @ Facebook Share This letter from FDA ?#socpharm

:
Thoughts anyone on T1? #socpharm

:
#socpharm @ T1 – at first, panic! Then “what can we do about it”

:
RT @: t1: What’s been the overall feedback/response to the @ Facebook Share This letter from FDA ? #socpharm

:
RT @: #socpharm @ T1 – at first, panic! Then “what can we do about it”

:
right panic first #socpharm

:
I love Wendy’s comment, bc it’s true that panic is the 1st response. We put out a POV about it and ppl appreciated the translation #socpharm

:
Repeating T1: any feedback/response to @ FB Share This ltr? #socpharm besides panic?

:
Agree #socpharm

:
@ herding cats! #socpharm is easier on the Internet ;). Checking in from Bolt bus to Boston

:
I think that with a lot of emerging media, marketers are nervous because it’s new territory. Pharma marketers doubly so #socpharm

:
Haven’t we all submitted to a practice of do first, ask forgiveness later? At least that’s our response. #socpharm

:
@ no way! Who wants to gamble that? I think it’s better to first ask experts, then have no forgiveness to ask. #socpharm

:
#socpharm Yes its new territory, new technology for many. Suddenly everyone learned quickly what metadata was!

:
Agree! RT @: Audience: Anyone who knows about metadata knows how it’s shared, doesn’t think it was malicious. #socpharm

:
RT @: #socpharm Yes its new territory, new technology for many. Suddenly everyone learned quickly what metadata was!

:
#socpharm Agree – doubt it was malicious or done with intent to harm/mislead. Perhaps just sloppy. Unfortunate but we all learned from it

:
No one wants to seem malicious, and no one wants to seem ignorant either #socpharm

:
@ Isn’t that why innovation is slow in Pharma? #socpharm

:
Re: meta data. Even if not malicious, it was still a pretty big oversight. Don’t blame the FDA at all. #socpharm

:
@ I still wouldn’t advise clients to act first if there’s a risk that they could be reprimanded #socpharm

:
Forgot #! Are we ready to move to T2? #socpharm

:
T2: How does pharma engage w/epatients & what’s appropriate level of involvement? #socpharm

:
Audience: we use epatient mentors nonpaid pts encouraged to talk to other pts, going to conference #socpharm

:
Great ans from @ RT @: We use epatient mentors nonpaid pts encouraged to talk 2 other pts, going to conference #socpharm

:
RT @: Audience: we use epatient mentors nonpaid pts encouraged to talk to other pts, going to conference #socpharm

:
#socpharm We’ve bn talking abt that in Stream B too – agencies must help clients stay on top of, ahead of SM technology, understand risks

:
What makes a valuable epatient? #socpharm

:
T2: Provide value, build trust. I think epatient will guide us re: level of involvement. #socpharm

:
Not my Q, some1 from front row RT @: RT @: “So where was the agency on this?” #socpharm <-- Glad you asked that.

:
Yes @: #socpharm we need help from agency partners to stay ahead and keep us on top of technology

:
Advice from an ePatient: be open (transparent) & don’t control convo – let patients tell you their concerns. #socpharm

:
RT @: Not my Q, some1 from front row RT @: RT @: “So where was the agency on this?” #socpharm <-- Glad you asked that.

:
RT @: Advice from an ePatient: be open (transparent) & don’t control convo – let patients tell you their concerns. #socpharm

:
RT @: Advice from an ePatient: be open (transparent) & don’t control convo – let patients tell you their concerns. #socpharm

:
Holy cow this #socpharm tweetchart is kind of hard to do…bravo to anyone who isn’t breaking a sweat like I am over here ginnydillon:

” target=”_blank”>RT @:
Advice from an ePatient: be open (transparent) & don’t control convo – let patients tell you their concerns. #socpharm

:
I agree w/ @ “e-patient” is not a “blogger”– it’s an empowered patient that is channel agnostic in their comm w/others #socpharm

:
RT @: I agree w/ @ “e-patient” is not a “blogger”– it’s an empowered pat that is channel agnostic #socpharm

:
T3: Create your own mobile APP or partner with already existing one? #socpharm

:
I keep getting fail whale #socpharm

:
@ epatients don’t need a blog or to be an influencer. Many just have a computer and are empowered to look for answers. #socpharm

:
RT @ epatients don’t need a blog or to be an influencer. Many just have a computer & are empowered to look for answers. #socpharm

:
@ @ @ See my interview w/ @ on e-patient @ blog: http://bit.ly/aZ0h88 #socpharm

:
I think when it comes to celeb vs. non-celeb, it’s whoever engages the most often. #socpharm

:
It’s the engagement that drives the trust, no? Familiarity w/someone b/c you see them on TV all the time vs b/c you see them IRL #socpharm

:
T3: depends on biz goals, audience need, existing apps… etc. Don’t reinvent the wheel if a good app exists, IMO. #socpharm

:
#socpharm celebrity advocate – tiger woods for STD? Bahaha pharma is funny!

:
True of all social media! RT @: I think when it comes to celeb vs. non-celeb, it’s whoever engages the most often. #socpharm

:
nice example of pharma pat advocate program @ & celebrity involvement that DOES communicates w/patient community #socpharm

:
But it also depends on the age group – think Nick Jonas for Bayer Diabetes Care…maybe a popstar has more impact on teens? #socpharm

:
Engagement (and the definition of what we mean by engagement) is the key to the epatient conversation. #socpharm

:
RT @: T3: Create your own mobile APP or partner with already existing one? #socpharm

:
T3: Depends. If building. Recycling the same idea/app + nothing new = no value. Build something unique. Or, build a better app! #socpharm

:
@ pointing out that not a lot known about how celebs manage their own diabetes. #socpharm

:
I rely on self 2 find info as savvy pt, I want to know ALL details inc info of unethical behavior behind any drug’s co I might use #socpharm

:
@ a patient on a forum or a blog, I can see the decisions made on a day-to-day basis. Not like Brett Michaels. #socpharm

:
RT @: I rely on self 2 find info as savvy pt, I want to know ALL details inc info of unethical behavior behind any drug’s co I might use #socpharm

:
From Custom Briefings – more penetration in the market for a patient with celebrity – online must be levered by major news outlets #socpharm

:
Audience: If he’s a celebrity, he doesn’t live my kind of life. #socpharm

:
Ok introducing T4 now #socpharm

:
RT @: Audience: If he’s a celebrity, he doesn’t live my kind of life. #socpharm

:
t4: How is pharma using private online communities or #sermo, @ & @ to build rleationships w/HCPs? #socpharm

:
T2, isn’t this more about paying real, everyday patients to speak on pharma’s behalf vs. celebrity spokesperson? #socpharm

:
Audience member points out teens may idolize celebs like Nick Jonas (for Bayer). #socpharm

:
Nick Jonas diabetes spokesperson for diabetes more relatable than Wilford Brimley! #socpharm

:
T4: How is pharma using private online communities or #sermo, @ & @ to build rleationships w/HCPs? #socpharm

:
Is it ethical to manipulate public trust w DTC ads via celebrity endorsements? #socpharm

:
Audience: shared BB King story which worked well but Patty LaBelle did not. #socpharm

:
RT @: Nick Jonas diabetes spokesperson for diabetes more relatable than Wilford Brimley! #socpharm

:
@ It is not ethical to manipulate ANYTHING with advertising #socpharm

:
Doesnt that depend on who ur reaching? RT @: Nick Jonas diabetes spokesperson more relatable than Wilford Brimley! #socpharm

:
@ Soon a Jonas insulin pump ?? #socpharm

:
yes, relateability with audience @ RT @ Audience says teens may idolize celebs (Nick Jonas for Bayer). #socpharm

:
RT @: t4: How is pharma using private online communities or #sermo, @ & @ to build rleationships w/HCPs? #socpharm

:
Re: Celebs #socpharm A little levity + celebs also works wonders. Example: http://ow.ly/2WzoB

:
Computer shut down during #socpharm tweetchat :-(

:
T4 challenge is how to find a participatory role vs. a controlling role #socpharm

:
Within3 RT @ RT @: t4: How is pharma using private online communities or #sermo, @ & @ w/HCPs? #socpharm

:
@ so audience can’t see screen? #socpharm

:
Why do we have 2 choose real epatients celebrities vs real epatients?why can’t brands build relationships w many epatients? #socpharm

:
I don’t have quick thumbs #socpharm

:
@ #socpharm Ah yes the agency hidden agendas again..we need …

:
were we just talking about physician celebrity spokespeople? I would buy anything from Dr. Sanjay Gupta ;-) #socpharm

:
influence of my decisions abt drug co choice is directly influenced by corporate crimes, fines for illegal marketing, buried data #socpharm

:
Thnx to @ for asking me to moderate – a first for me #socpharm

:
@ I think it comes with a matching lunchbox, lol. #socpharm #digipharm

:
Enjoyed all the new insight from #socpharm #digipharm

:
Yay that’s me :-) RT @: Audience member points out teens may idolize celebs like Nick Jonas (for Bayer). #socpharm

:
#socpharm Aren’t patients- celebrity or not- still patients? A celeb w cancer = human w/ cancer. A chttp://tl.gd/6ir778

:
RT @: #socpharm Aren’t celeb patients still patients? A celeb w cancer = human w/ cancer. A c http://tl.gd/6ir778 -nicely put

:
@ join #socpharm tweetchat at our regular time at 8 pm est on Wednesdays.

:
Thx for a fun #socpharm live tweetchat – nice job @ @ @ (sorry my bttry died and wifi pooped midstream)

About Eileen O'Brien

Eileen has more than 16 years of digital healthcare marketing experience. She is an opinion leader on social media and biopharma, and has been invited to speak at industry conferences and quoted in publications.

View other posts from Eileen

Siren Interactive
  • Siren Interactive
  • Rare Disease Relationship Marketing Experts
  • 626 West Jackson Blvd, Suite 100
  • Chicago, IL 60661
  • 312.204.6700
  • 866.502.6714 (Toll Free)
  • www.sireninteractive.com